Literature DB >> 35511431

The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge.

Ruixue Hou1, Lewis E Tomalin1, Jessica Pintado Silva2, Seunghee Kim-Schulze3, Stephen S Whitehead4, Ana Fernandez-Sesma2, Anna P Durbin5,6, Mayte Suárez-Fariñas1,7.   

Abstract

Understanding the immune response to dengue virus (DENV) is essential for developing a dengue vaccine that is protective against all 4 DENV serotypes. We evaluated the immune response after vaccination (live attenuated tetravalent dengue vaccine TV005 or trivalent admixture) and after challenge with DEN2Δ30 (Tonga/74) to better understand the importance of homotypic immunity in vaccine protection. Significant increases in IP-10 expression were observed following receipt of either the trivalent or tetravalent vaccine. After challenge, a large increase in IP-10 expression was observed in the placebo and trivalent admixture groups but not in the tetravalent vaccine group. MCP-1, IL-1RA, and MIP-1β exhibited a similar pattern as IP-10. These results demonstrate protective effects of trivalent and tetravalent vaccines against DENV and suggest that the tetravalent vaccine has a better protective effect compared with the trivalent admixture. We also explored the postvaccination and postchallenge immune response differences between Black and White participants. White participants responded to vaccine differently than Black participants; Black participants receiving trivalent and tetravalent vaccines responded strongly and White participants responded only transiently in trivalent group. In response to challenge, White participants elicited a stronger response than Black participants. These results may explain why White participants may have a more vigorous DENV immune response than Black participants, as reported in literature.

Entities:  

Keywords:  Immunology; Infectious disease; Innate immunity

Mesh:

Substances:

Year:  2022        PMID: 35511431      PMCID: PMC9220850          DOI: 10.1172/jci.insight.157811

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  32 in total

1.  Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981.

Authors:  G P Kouri; M G Guzmán; J R Bravo; C Triana
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

2.  Elevated levels of vascular endothelial growth factor in adults with severe dengue infection.

Authors:  Preeti Thakur; Anita Chakravarti; Sunita Aggarwal; Beena Uppal; Preena Bhalla
Journal:  Virusdisease       Date:  2016-02-02

3.  Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation.

Authors:  Marcin Kwissa; Helder I Nakaya; Nattawat Onlamoon; Jens Wrammert; Francois Villinger; Guey Chuen Perng; Sutee Yoksan; Kovit Pattanapanyasat; Kulkanya Chokephaibulkit; Rafi Ahmed; Bali Pulendran
Journal:  Cell Host Microbe       Date:  2014-06-26       Impact factor: 21.023

4.  Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.

Authors:  Joseph E Blaney; Jennifer M Matro; Brian R Murphy; Stephen S Whitehead
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Dengue: clinical forms and risk groups in a high incidence city in the southeastern region of Brazil.

Authors:  Ivana Macedo Cardoso; Aline de Souza Areias Cabidelle; Patrícia de Castro E Leão Borges; Carolina Ferreira Lang; Fabrício Greco Calenti; Larissa de Oliveira Nogueira; Aloisio Falqueto; Crispim Cerutti Junior
Journal:  Rev Soc Bras Med Trop       Date:  2011-07-22       Impact factor: 1.581

6.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

7.  Circulating Progenitor Cells and Racial Differences.

Authors:  Ayman Samman Tahhan; Muhammad Hammadah; Heval Mohamed Kelli; Jeong Hwan Kim; Pratik B Sandesara; Ayman Alkhoder; Belal Kaseer; Mohamad Mazen Gafeer; Matthew Topel; Salim S Hayek; Wesley T O'Neal; Malik Obideen; Yi-An Ko; Chang Liu; Iraj Hesaroieh; Ernestine Mahar; Viola Vaccarino; Edmund K Waller; Arshed A Quyyumi
Journal:  Circ Res       Date:  2018-08-03       Impact factor: 17.367

Review 8.  Dengue vaccine: Global development update.

Authors:  Eakachai Prompetchara; Chutitorn Ketloy; Stephen J Thomas; Kiat Ruxrungtham
Journal:  Asian Pac J Allergy Immunol       Date:  2020-09       Impact factor: 2.310

9.  Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.

Authors:  Janet C Lindow; Nathan Borochoff-Porte; Anna P Durbin; Stephen S Whitehead; Kelly A Fimlaid; Janice Y Bunn; Beth D Kirkpatrick
Journal:  PLoS Negl Trop Dis       Date:  2012-07-17

10.  Slow resolution of inflammation in severe adult dengue patients.

Authors:  Lingzhai Zhao; Xiuyan Huang; Wenxin Hong; Shuang Qiu; Jian Wang; Lei Yu; Yaoying Zeng; Xinghua Tan; Fuchun Zhang
Journal:  BMC Infect Dis       Date:  2016-06-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.